



Citation for published version:

Orbai, A-M, Holland, R, Leung, YY, Tillett, W, Goel, N, Christensen, R, McHugh, N, Gossec, L, de Wit, M, Højgaard, P, Coates, LC, Mease, PJ, Birt, J, Fallon, L, FitzGerald, O, Ogdie, A, Shea, B, Strand, V, Callis Duffin, K, Tugwell, P, Beaton, D & Gladman, DD 2019, 'PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials', *The Journal of Rheumatology*, vol. 46, no. 1, pp. 990-995. <https://doi.org/10.3899/jrheum.181077>

DOI:

[10.3899/jrheum.181077](https://doi.org/10.3899/jrheum.181077)

Publication date:

2019

Document Version

Peer reviewed version

[Link to publication](#)

This is a pre-copy-editing, author-produced PDF of an article accepted for publication in *The Journal of Rheumatology* following peer review. The definitive publisher-authenticated version Ana-Maria Orbai, Richard Holland, Ying Ying Leung, William Tillett, Niti Goel, Robin Christensen, Neil McHugh, Laure Gossec, Maarten de Wit, Pil Højgaard, Laura C. Coates, Philip J. Mease, Julie Birt, Lara Fallon, Oliver FitzGerald, Alexis Ogdie, Beverly Shea, Vibeke Strand, Kristina Callis Duffin, Peter Tugwell, Dorcas Beaton, Dafna D. Gladman, 'PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials', *The Journal of Rheumatology* Aug 2019, 46 (8) 990-995, is available online at: [10.3899/jrheum.181077](https://doi.org/10.3899/jrheum.181077)

University of Bath

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Supplement Table 1. Feedback from OMERACT participants on the PsAID12

<p>Discussion points by topic</p> <p>Overall process and evidence</p> <ul style="list-style-type: none"> • <i>It was noted that a significant amount of work had gone into appraising the instruments, and that both were backed by a substantial body of evidence.</i> • <i>A number of participants felt that the instrument could achieve an overall “Green” rating given the body of evidence supporting Domain Match, Feasibility and Construct validity, whereas other participants felt that discrimination was a critical aspect of an instrument and that an “Amber” rating in any of the discrimination sub-categories should result in an overall “Amber” rating.</i> • <p>Content validity</p> <ul style="list-style-type: none"> • <i>It was noted that the PsAID questionnaire captures items that may not be relevant to all patients, and concerns around how this might impact the overall score. There were also some concerns regarding the anchors used.</i> • <i>Whether patients could conceptualize “due to psoriatic arthritis” is referring to their condition if they do not have arthritis manifestations. Probably not a major concern, as patients voted positively for domain match. Whether patients ratings for items like embarrassment/ fatigue/ others can really differentiate that it is effect of Psoriatic arthritis rather than other comorbidities (disease attribution)</i> <p>Feasibility</p> <ul style="list-style-type: none"> • <i>Weighted scores impact feasibility.</i> <p>Construct validity</p> <ul style="list-style-type: none"> • <i>Potentially different constructs simultaneously assessed by items work/leisure (#4), anxiety/fear/uncertainty (#9), embarrassment/shame (#10)</i> • <i>Concern these items may not be as sensitive to change with treatment.</i> <p>Discrimination</p> <ul style="list-style-type: none"> • <i>Some confusion regarding the use of a LOS to assess discrimination, with many people in the breakout group believing that this evidence has to come from an RCT. Some participants felt that discrimination in clinical trials was a critical aspect for an instrument, particularly as the objective is to find instruments to be used in RCTs, and this was noted to be especially important to Industry. One of 8 breakout groups suggested RCT discrimination should have been white rather than amber (15/17).</i> • <i>OMERACT TAG has clarified that cohort study longitudinal data can be taken as bronze level evidence. Since RCT information is missing can proceed with amber based on LOS and mandatory to address the gaps of knowledge: RCT data. Research agenda: RCT discrimination and Thresholds of meaning.</i> <p>Suggestions</p> <ul style="list-style-type: none"> • <i>Skin item (#3): change attribution to psoriasis instead of psoriatic arthritis.</i> • <i>Inconsistency across anchors for the 12 items when some would prefer consistent anchors.</i> <p>Other</p> <ul style="list-style-type: none"> • <i>Based on PsAID12 we cannot calculate utilities or economic analysis. There may be interpretability of some questions.</i> • <i>Overlap with other domains such as physical function and fatigue was noted.</i> <p>Agreement with PsAID12 amber (or better) endorsement as core instrument for PsA RCTs and LOS across breakout groups (all considered together): 71/81 (88%)</p>
--